1-N,4-N-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide | 500538-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-N,4-N-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide
• CAS: 500538-94-3
• 化学式: C₃₄H₂₄N₆O₂
• 分子量: 548.6
• InChiKey: WSXIJTIFOWCMIQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.410±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO: 2mg/mL, clear

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
  申请人：Jorcyk Cheryl

  公开号：US10286070B2

  公开（公告）日：2019-05-14

  A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.

  提供了一种治疗癌症或转移瘤的方法，该方法涉及对受试者施用至少一种OncOStatin M（OSM）拮抗剂，其中受试者已被诊断患有癌症。提供了一种 OSM 拮抗剂（如小分子药物）以及一种抗 OSM 抗体、一种抗 OSM 合酶和一种 OSM mRNA 拮抗剂。研究发现，OSM拮抗剂可抑制或防止几种癌症类型的肿瘤细胞脱落、增殖和转移。
• Methods and compositions for the treatment of tuberculosis
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US11529354B2

  公开（公告）日：2022-12-20

  Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

  本文提供了治疗结核病的方法和组合物，包括协同组合物。
• LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：EP2567225A2

  公开（公告）日：2013-03-13
• COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：EP2897632A2

  公开（公告）日：2015-07-29
• USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：US20150337018A1

  公开（公告）日：2015-11-26

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.